Trial Information
A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy
Inclusion Criteria:
- Patients with a histologically proven advanced solid malignancy for which no
recognized therapy was available or for which standard therapy had failed
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function
Exclusion Criteria:
- Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
or an investigational agent within 4 weeks before the start of study treatment
- Subjects had to have recovered from all prior treatment toxicities, except alopecia,
and from any major surgery.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Maximum Tolerated Dose (MTD)
Outcome Time Frame:
18-Nov-2008
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
RTKD-7840-002
NCT ID:
NCT00982267
Start Date:
December 2003
Completion Date:
June 2011
Related Keywords:
- Neoplasms
- Solid Tumors
- cancer
- Neoplasms